Tolvaptan (Samsca) - Important Safety Information from Otsuka as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 03/04/2012

 

Problem Or Issue:
Important Safety Information communication from Otsuka on the risks of increases in serum sodium which are too rapid when using Tolvaptan (Samsca) and how to minimise the risks.

Important Safety Information - Tolvaptan (Samsca)


« Back